Market Research Logo

Non-Small Cell Lung Cancer (NSCLC) - Current and Future Players

Non-Small Cell Lung Cancer (NSCLC) - Current and Future Players

Summary

GlobalData has released its pharma report, “Non-Small Cell Lung Cancer (NSCLC) - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing NSCLC Market. The report identifies and analyses the key companies shaping and driving the global NSCLC market. The report provides insight into the competitive NSCLC landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Scope

  • Investigation of current and future market competition for NSCLC
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of NSCLC sector through market impact analysis, future market scenario and company analysis
Reasons to buy
  • Gain a high level view of the trends shaping and driving NSCLC market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What’s the next big thing in the global NSCLC market landscape? Identify, understand and capitalize


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Market Outlook
3.1 Global Markets
3.1.1 Forecast
3.1.2 Drivers and Barriers - Global Issues
4 Current and Future Players
4.1 Overview
4.2 Trends in Corporate Strategy
4.3 Company Profiles
4.3.1 Roche/Genentech
4.3.2 Eli Lilly
4.3.3 Pfizer
4.3.4 AstraZeneca
4.3.5 Bristol-Myers Squibb
4.3.6 Merck & Co.
4.3.7 Novartis
4.3.8 Boehringer Ingelheim
5 Appendix
5.1 Bibliography
5.2 Abbreviations
5.3 Methodology
5.4 Forecasting Methodology
5.4.1 Diagnosed NSCLC Patients
5.4.2 Percent Drug-Treated Patients
5.4.3 Drugs Included in Each Therapeutic Class
5.4.4 Launch and Patent Expiry Dates
5.4.5 General Pricing Assumptions
5.4.6 Individual Drug Assumptions
5.4.7 Generic Erosion
5.4.8 Pricing of Pipeline Agents
5.5 Primary Research - KOLs
5.5.1 KOLs
5.6 About the Authors
5.6.1 Analyst
5.6.2 Therapy Area Director
5.6.3 Epidemiologist
5.6.4 Global Head of Healthcare
5.7 About GlobalData
5.8 Disclaimer
1.1 List of Tables
Table 1: NSCLC - Global Drivers and Barriers, 2015‒2025
Table 2: Key Companies in the NSCLC Market in the 8MM, 2015-2025
Table 3: Roche/Genentech’s NSCLC Portfolio Assessment, 2016
Table 4: Eli Lilly’s NSCLC Portfolio Assessment, 2016
Table 5: Pfizer’s NSCLC Portfolio Assessment, 2016
Table 6: AZ’s NSCLC Portfolio Assessment, 2016
Table 7: BMS’ NSCLC Portfolio Assessment, 2016
Table 8: Merck & Co.’s NSCLC Portfolio Assessment, 2016
Table 9: Novartis’ NSCLC Portfolio Assessment, 2016
Table 10: BI’s NSCLC Portfolio Assessment, 2016
Table 11: Key Launch Dates - Part I
Table 12: Key Launch Dates - Part II
Table 13: Key Patent Expiries
Table 14 Average Body Weight and Surface Area Across the 8MM
Table 15: Average Cost of Therapy of Alimta in the 8MM
Table 16: Average Cost of Therapy of Alecensa in the 8MM
Table 17: Average Cost of Therapy of Avastin
Table 18: Average Cost of Therapy of Cyramza
Table 19: Average Cost of Therapy of Gilotrif
Table 20: Average Cost of Therapy of Iressa
Table 21: Average Cost of Therapy of Portrazza
Table 22: Average Cost of Therapy of Tagrisso
Table 23: Average Cost of Therapy of Tarceva
Table 24: Average Cost of Therapy of Vargatef
Table 25: Average Cost of Therapy of Xalkori
Table 26: Average Cost of Therapy of Zykadia
Table 27: Average Cost of Therapy of Keytruda
Table 28: Average Cost of Therapy of Opdivo
Table 29: Average Cost of Therapy of Tecentriq
Table 30: Average Cost of Therapy of Conmana
Table 31: High-Prescribing Physicians Surveyed by Country
1.2 List of Figures
Figure 1: Global Sales for NSCLC (8MM), 2015-2025
Figure 2: Global Sales for NSCLC (8MM), 2015-2025
Figure 3: Global Sales for NSCLC (8MM), 2015-2025
Figure 4: Global Sales of Branded Products for NSCLC by Company, 2015-2025
Figure 5: Company Portfolio Gap Analysis in NSCLC, 2015-2025
Figure 6: Roche/Genentech SWOT Analysis in NSCLC, 2016
Figure 7: Eli Lilly SWOT Analysis in NSCLC, 2016
Figure 8: Pfizer SWOT Analysis in NSCLC, 2016
Figure 9: AZ SWOT Analysis in NSCLC, 2016
Figure 10: BMS SWOT Analysis in NSCLC, 2016
Figure 11: Merck & Co. SWOT Analysis in NSCLC, 2016
Figure 12: Novartis SWOT Analysis in NSCLC, 2016
Figure 13: BI SWOT Analysis in NSCLC, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report